MRK enters the final week of September with fresh firepower: a $400M upfront, $2.13B…
Premium · Advanced plan
Read the full MRK Stock Report on ORTEX
The full multi-page analysis — short-interest history, options flow, analyst movement, valuation, and outlook — is available on the Advanced plan in ORTEX.
Read full report on ORTEX →Previous versions
MRK Gives Back 4% as Shorts Rebuild and the Street Reassesses
Version 13Sep 7, 2026Merck Hits a 17% Monthly High as the Street Chases a Turning Point
Version 11Aug 24, 2026MRK Has Run Through Analyst Targets — Now What?
Version 10Aug 17, 2026MRK's Upgrade Cycle Hardens as Insiders Cash In at 12-Month Highs
Version 9Aug 10, 2026MRK Digests Its Q2 Print and Finds a New Footing
Version 8Aug 3, 2026MRK Steps Up to Q2 Results After Its Strongest Run in Years
Version 7Jul 27, 2026MRK Heads Into Q2 Earnings on Its Best Footing in Years
Version 6Jul 20, 2026MRK Rebounds on FDA Win, with Earnings in View
Version 5Jul 6, 2026MRK Breaks $129 as Bulls and Bears Swap Positions
Version 4Jun 8, 2026MRK: Gardasil Overhang Clears as Stock Finds Its Footing at $121
Version 3Jun 1, 2026MRK: ASCO Data Lifts the Story as Options Hedges Finally Ease
Version 1Apr 27, 2026Merck Heads Into Q1 Print Down 6% With Shorts Retreating
About ORTEX Stock Reports
Stock Reports are weekly long-form pieces written from ORTEX's own datasets — short interest, securities-lending, options flow, analyst movement, institutional positioning, valuation, and news — combined with the company's recent ORTEX coverage to keep the analysis consistent with what was published before.
Bodies are intentionally not available on ortex.news — the report is the headline Advanced-plan benefit. The opening is preserved here so readers can see which names are being covered each week.